VIA
CTMX icon

Vident Investment Advisory’s CytomX Therapeutics CTMX Stock Holding History

Vident Investment Advisory’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-104,365
Closed -$1.12M – 488
2019
Q1 		$1.12M Sell
104,365
-2,355
-2% -$34.8K 0.06% 395
2018
Q4 		$1.61M Buy
106,720
+13,058
+14% +$194K 0.09% 304
2018
Q3 		$1.73M Sell
93,662
-6,242
-6% -$142K 0.07% 357
2018
Q2 		$2.28M Buy
99,904
+20,761
+26% +$530K 0.09% 302
2018
Q1 		$2.17M Buy
79,143
+21,500
+37% +$614K 0.09% 301
2017
Q4 		$1.22M Sell
57,643
-27,896
-33% -$578K 0.05% 349
2017
Q3 		$1.55M Buy
85,539
+2,147
+3% +$33.5K 0.08% 308
2017
Q2 		$1.29M Buy
83,392
+7,468
+10% +$113K 0.11% 291
2017
Q1 		$1.31M Buy
75,924
+12,652
+20% +$167K 0.13% 288
2016
Q4 		$695K Sell
63,272
-4,124
-6% -$50K 0.08% 316
2016
Q3 		$1.06M Sell
67,396
-325
-0.5% -$3.93K 0.14% 271
2016
Q2 		$692K Sell
67,721
-6,109
-8% -$69.7K 0.1% 321
2016
Q1 		$952 Buy
73,830
+35,328
+92% +$491K 0.06% 353
2015
Q4 		$804K Buy
+38,502
New +$609K 0.1% 331

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vident Investment Advisory's CTMX Position: Q2 2019 in Review

Vident Investment Advisory sold out of CytomX Therapeutics (CTMX) in Q2 2019, closing a stake of 104,365 shares — an estimated $1.12M sold.

Vident Investment Advisory first reported a position in CTMX in Q4 2015 and held it in 14 quarters. The position peaked at $2.28M in Q2 2018. 109 funds tracked by Wall St. Rank hold CTMX as of Q2 2019.

  • Vident Investment Advisory reported no remaining CytomX Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Vident Investment Advisory sold 104,365 CytomX Therapeutics shares in Q2 2019, an estimated $1.12M.
  • Vident Investment Advisory first reported a position in CytomX Therapeutics in Q4 2015 and held it in 14 quarters.
  • Vident Investment Advisory's CytomX Therapeutics position peaked at $2.28M in Q2 2018.
  • 109 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2019.

Based on Vident Investment Advisory's 13F filing for Q2 2019, filed 12 Aug 2019.